Development of chimeric antigen receptors targeting the γδ T cell receptor.
Scientists developed CAR-T cells that specifically target rare gamma-delta T-cell cancers without harming normal immune cells.
The NCI team led by Kochenderfer developed CARs targeting the γδ TCR chain, creating a novel tool to selectively eliminate γδ T cell lymphomas and leukemias without off-target effects on conventional αβ T cells. This approach addresses a critical gap in CAR-T development for γδ T cell malignancies, which lack good surface targets that don't also appear on normal T cells, and opens a pathway toward clinical translation.
What the study was
- Study design
- Preclinical study
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Mol Ther Oncol
Why it surfaced
NCI/Kochenderfer lab is a leading CAR-T group; γδ TCR-targeting CARs are a novel and clinically unmet approach; PMC open access; γδ T cell lymphomas are rare with very limited therapeutic options.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.